Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Roussou

Showing results (31-40 of 71) with videos related to

Pageof 8
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|September 19, 2018
Elevated vWF Antigen Serum Levels Are Associated With Poor Prognosis, and Decreased Circulating ADAMTS-13 Antigen Levels Are Associated With Increased IgM Levels and Features of WM but not Increased vWF Levels in Patients With Symptomatic WMMaria Gavriatopoulou, Evangelos Terpos, Ioannis Ntanasis-Stathopoulos, et al.
American Journal of Hematology|January 13, 2015
Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategiesEfstathios Kastritis, Maria Roussou, Maria Gavriatopoulou, et al.
Haematologica|October 30, 2016
Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myelomaEfstathios Kastritis, Evangelos Terpos, Maria Roussou, et al.
American Journal of Hematology|May 30, 2012
Diffuse pattern of bone marrow involvement on magnetic resonance imaging is associated with high risk cytogenetics and poor outcome in newly diagnosed, symptomatic patients with multiple myeloma: a single center experience on 228 patientsLia A Moulopoulos, Meletios A Dimopoulos, Efstathios Kastritis, et al.
Haematologica|November 21, 2007
Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasoneEfstathios Kastritis, Athanasios Anagnostopoulos, Maria Roussou, et al.
British Journal of Haematology|August 15, 2023
Outcomes of patients with light chain (AL) amyloidosis after failure of daratumumab-based therapyFoteini Theodorakakou, Despina Fotiou, Vasiliki Spiliopoulou, et al.
British Journal of Haematology|July 13, 2010
High levels of serum angiogenic growth factors in patients with AL amyloidosis: comparisons with normal individuals and multiple myeloma patientsEfstathios Kastritis, Maria Roussou, Michalis Michael, et al.
American Journal of Hematology|February 19, 2016
Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysisMeletios A Dimopoulos, Maria Roussou, Maria Gavriatopoulou, et al.
British Journal of Haematology|February 7, 2024
Thrombotic and bleeding complications in patients with AL amyloidosisDespina Fotiou, Foteini Theodorakakou, Sotiria Spiliopoulou, et al.
European Journal of Haematology|May 19, 2010
High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agentsEvangelos Terpos, Eirini Katodritou, Maria Roussou, et al.
Pageof 8

Showing results (31-40 of 71) with videos related to

Sort By:
Pageof 8
Clinical Lymphoma, Myeloma & Leukemia|September 19, 2018
Elevated vWF Antigen Serum Levels Are Associated With Poor Prognosis, and Decreased Circulating ADAMTS-13 Antigen Levels Are Associated With Increased IgM Levels and Features of WM but not Increased vWF Levels in Patients With Symptomatic WMMaria Gavriatopoulou, Evangelos Terpos, Ioannis Ntanasis-Stathopoulos, et al.
American Journal of Hematology|January 13, 2015
Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategiesEfstathios Kastritis, Maria Roussou, Maria Gavriatopoulou, et al.
Haematologica|October 30, 2016
Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myelomaEfstathios Kastritis, Evangelos Terpos, Maria Roussou, et al.
American Journal of Hematology|May 30, 2012
Diffuse pattern of bone marrow involvement on magnetic resonance imaging is associated with high risk cytogenetics and poor outcome in newly diagnosed, symptomatic patients with multiple myeloma: a single center experience on 228 patientsLia A Moulopoulos, Meletios A Dimopoulos, Efstathios Kastritis, et al.
Haematologica|November 21, 2007
Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasoneEfstathios Kastritis, Athanasios Anagnostopoulos, Maria Roussou, et al.
British Journal of Haematology|August 15, 2023
Outcomes of patients with light chain (AL) amyloidosis after failure of daratumumab-based therapyFoteini Theodorakakou, Despina Fotiou, Vasiliki Spiliopoulou, et al.
British Journal of Haematology|July 13, 2010
High levels of serum angiogenic growth factors in patients with AL amyloidosis: comparisons with normal individuals and multiple myeloma patientsEfstathios Kastritis, Maria Roussou, Michalis Michael, et al.
American Journal of Hematology|February 19, 2016
Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysisMeletios A Dimopoulos, Maria Roussou, Maria Gavriatopoulou, et al.
British Journal of Haematology|February 7, 2024
Thrombotic and bleeding complications in patients with AL amyloidosisDespina Fotiou, Foteini Theodorakakou, Sotiria Spiliopoulou, et al.
European Journal of Haematology|May 19, 2010
High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agentsEvangelos Terpos, Eirini Katodritou, Maria Roussou, et al.
Pageof 8